ArriVent BioPharma, Inc. (AVBP) Stock AnalysisAVBPStock AnalysisArriVent BioPharma, Inc.

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It is focused on maximizing the potential of its lead development candidate, firmonertinib, and advancing a pipeline of novel therapeutics, such as antibody drug conjugates (ADCs), through approval and commercialization. Firmonertinib is an oral, highly brain-penetrant, and broadly active mutation-selective epidermal growth factor receptor (EGFR) inhibitor active against both classical and uncommon EGFR mutations, including PACC and exon 20 insertion mutations. It is developing ARR-217, an ADC for the treatment of gastrointestinal cancers. Its ARR-002 is a Mucin-16 (MUC16) and sodium-dependent phosphate transport protein 2b (NaPi2b) dual-target, tetravalent (2+2 format) ADC, with site-specific conjugation to vcMMAE at a drug-to-antibody ratio (DAR) of 4. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Arrivent Biopharma Inc is a good buy right now due to its recent price increase of 3.61% over the last 5 days and a significant year-to-date change of 45.05%. The current price of $30.17 is well below the analyst price target of $45, suggesting a potential upside of 49%. However, the company is currently facing negative net income, with a loss of $49,893,000 reported for Q2 2026, which is a risk to consider.